08 · WHY THIS SITE EXISTS
About this BPC-157 TB-500 study guide
You get the animal findings, the missing human facts, and the current federal status. The blend has no proved benefit, dose, or safety record.
What can this guide tell you about the blend?
Rat and mouse work supplied the clearest findings. Those changes belong to the animals studied. Human facts remain scarce. Each result also belongs to the one part that researchers tested.
No clinic runs Legit Wolverine. Nobody here sees patients, writes prescriptions, or sells a product. That means the site cannot judge your knee or choose care. A doctor or clinic must handle those questions.
“Wolverine” is a seller and research-group name. It means the BPC-157 and TB-500 pair. The name does not define an approved drug. A product claim still needs human proof.
A rat result may support more research. It cannot predict what happens to your tendon or wound. Missing human safety facts leave benefit and risk unknown. No seller can supply those missing facts.
What does “legit” mean for a claim about this blend?
A sound claim must match the study behind it. Most findings came from one part tested in animals [9]. No human study proves the pair works. A seller's claim cannot turn separate rat studies into your likely result.
FDA's current page records both nominations as withdrawn. Both parts are outside Category 2 now. Staff advised against pharmacy mixing before the July 2026 meeting [12][13]. The page does not show approval or clear pharmacy permission.
As of September 2026, FDA had not posted the members' vote. Without that record, the meeting cannot settle access. The blend has no approval and no proved dose. Those are the firm limits for a clinic or pharmacy.
Your choice starts with what is known. Rat findings may be hopeful. Those findings still cannot promise how your body heals. The missing proof is a study of the human blend.
Which facts matter before you trust a claim?
Some studies used full Thymosin Beta-4 [4][8]. The sold TB-500 form is shorter. A full-protein result may not apply to the sold form. It also says nothing about the two-part blend.
FDA's current page covers medicine mixed for one patient. The page does not show that a 2026 meeting put either part in Category 2. A pharmacy must follow the current rule. Meeting talk alone does not change access.
Before the July 2026 meeting, FDA staff advised against adding both parts. FDA posted no final vote record. Without a vote or new rule, the meeting did not change access. That is the clearest answer the public record gives.